The Combination of PECS II Block and Parasternal Block for Radical Mastectomy
NCT ID: NCT03754816
Last Updated: 2019-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
65 participants
INTERVENTIONAL
2018-12-01
2019-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anesthetic Efficacy of PECS II Block and Parasternal Block
NCT03016117
Pecs II Block and PaB Could be an Alternative in Breast Surgery
NCT02865265
PECS and Parasternal Block for Breast Surgery
NCT03043755
Continuous Serrates Plane Block in Axillary Dissection
NCT03992859
The Analgesic Efficacy of the Pectoral Block After Mastectomy
NCT02916381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
PECS II and parasternal block
10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
Levobupivacaine
Levobupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PECS II and parasternal block
10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
Levobupivacaine
Levobupivacaine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients undergoing to radical mastectomy with axillary dissection and breast-implant reconstruction
Exclusion Criteria
* ASA status patients: 4
* breast anatomy abnormalities
* neurological diseases
* septic conditions
* coagulopathies
* drug abuse history
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
San Salvatore Hospital of L'Aquila
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emiliano Petrucci
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emiliano Petrucci
Role: PRINCIPAL_INVESTIGATOR
San Salvatore Academic Hospital of L'Aquila
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Salvatore Academic Hospital
Coppito, L'Aquila, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0180910/16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.